BDX Becton, Dickinson and Company

NYSE
$177.85

Becton, Dickinson and Company (BDX) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with BDX's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 4 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
5
22 transactions
Purchases
$0
0 shares
Sales
$2.8M
15,916 shares
Net activity
-$2.8M
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $11.8K 1 transaction · 75 shares
Discretionary sales $2.8M 21 transactions · 15,841 shares

Largest single sale: $768.1K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Feld Michael EVP, Chief Revenue Officer Sell 165 $188.49 $31.1K 19,720 −0.8% of holding
Polen Thomas E Jr Chairman, CEO and President Sell 4,152 $185.00 $768.1K 110,163 −3.6% of holding
Goette Roland EVP and President, EMEA Sell 2,438 $180.84 $440.9K 14,856 −14.1% of holding
Feld Michael EVP, Chief Revenue Officer Sell 75 $157.13 $11.8K 20,934 −0.4% of holding
Feld Michael EVP, Chief Revenue Officer Sell 75 $152.80 $11.5K 21,009 −0.4% of holding
Garrison Michael David EVP & Pres Med.Essntl&BioPharm Sell 1,100 $145.66 $160.2K 13,172 −7.7% of holding
Garrison Michael David EVP & Pres Med.Essntl&BioPharm Sell 1,100 $151.48 $166.6K 14,272 −7.2% of holding
Polen Thomas E Jr Chairman, CEO and President Sell 2,764 $146.35 $404.5K 110,163 −2.4% of holding
Feld Michael EVP, Chief Revenue Officer Sell 75 $147.35 $11.1K 21,084 −0.4% of holding
Feld Michael EVP, Chief Revenue Officer Sell 74 $151.94 $11.2K 21,159 −0.3% of holding
Feld Michael EVP, Chief Revenue Officer Sell 10b5-1 75 $156.83 $11.8K 21,233 −0.4% of holding
Feld Michael EVP, Chief Revenue Officer Sell 75 $181.84 $13.6K 21,308 −0.4% of holding
SCOTT BERTRAM L Director Sell 953 $182.61 $174.0K 36,763 −2.5% of holding
Feld Michael EVP, CRO & Pres. Life Sciences Sell 75 $202.73 $15.2K 16,431 −0.5% of holding
Garrison Michael David 2 fills EVP & Pres Med.Essntl&BioPharm Sell 1,610 $207.46 $334.0K 13,105 −10.9% of holding
Feld Michael EVP, CRO & Pres. Life Sciences Sell 74 $196.08 $14.5K 16,506 −0.4% of holding
Garrison Michael David EVP & Pres Med.Essntl&BioPharm Sell 629 $196.03 $123.3K 13,105 −4.6% of holding
Feld Michael EVP, CRO & Pres. Life Sciences Sell 75 $193.36 $14.5K 16,580 −0.5% of holding
SCOTT BERTRAM L Director Sell 217 $176.58 $38.3K 35,816 −0.6% of holding
Feld Michael EVP & President, Life Sciences Sell 57 $186.01 $10.6K 8,245 −0.7% of holding
Feld Michael EVP & President, Life Sciences Sell 58 $181.03 $10.5K 8,302 −0.7% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.